Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-center, Single-arm, Open-label Clinical Study of Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy

Next Previous
Trial Profile

A Single-center, Single-arm, Open-label Clinical Study of Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fruquintinib (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary) ; Raltitrexed (Primary) ; Tislelizumab (Primary)
  • Indications Colorectal cancer; Liver metastases
  • Focus Therapeutic Use

Most Recent Events

  • 04 Jun 2024 Results of updated analysis of survival, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 23 May 2024 According to a HUTCHMED media release, data from this study will be presented at the upcoming American Society of Clinical Oncology Annual Meeting, taking place May 31 - June 4, 2024 in Chicago, IL and online.
  • 15 Jan 2024 Planned End Date changed from 1 Jun 2024 to 1 Feb 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top